Fig. 4

SLC1A1-mediated glutamine addition and malignant phenotype in NKTCL.

(a, b, and c) SLC1A1 expression (a), cell proliferation (b) and colony formation (c) of NK-92 cells transfected with SLC1A1 vector or control vector and SNK-6 cells transfected with SLC1A1 shRNA or scramble.

(d) Cell viability of NK-92 cells transfected with SLC1A1 vector or control vector under glutamine-depleted medium.

(e and f) Cell growth inhibition (e) and colony formation (f) of NK-92 cells transfected with SLC1A1 vector under indicated culture medium.

(g) IC50 of NK-92 cells transfected with SLC1A1 vector or control vector and SNK-6 cells transfected with SLC1A1 shRNA or scramble treated with asparaginase.

(h) Tumor formation of NK-92 cells transfected with SLC1A1 vector or control vector under indicated number of injected cells in xenograft zebrafish models.

(i) Survival of xenograft zebrafish models injected with NK-92 cells transfected with SLC1A1 vector or control vector upon asparaginase treatment (0.5 IU/mL).

All the assays were set up in triplicate. Data in (a), (b), (c), (d), (e), (f), (g) and (h) were represented as mean ± SD. P values in (a), (b), (c), (d), (e), (f), (g) and (h)were calculated with unpaired t-test. P values in (i) were calculated with log-rank test.